Molecular Diagnostics
News on lab-developed tests and emerging diagnostic technologies.
Variantyx Combines Long Nanopore, Short Illumina Reads for Rare Disease Whole-Genome Diagnostic Test
Premium
The firm recently launched the Genomic Unity 2.0 assay, which it claims is the first commercial diagnostic rare disease test to include nanopore sequencing.
Foundation Medicine Test Approved by FDA as CDx for Itovebi in Breast Cancer Patients
The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.
Burning Rock, Dizal Get Chinese Approval for Lung Cancer CDx
The test, approved by Chinese regulators in early 2022, is designed for the detection of multiple mutation statuses for nine genes.
Xgenera has also closed a round of seed financing worth £500,000 and commenced a partnership with YouSeq, a UK technology firm.
Delve Bio, Broad Clinical Labs Partner for Metagenomic Infectious Disease Sequencing
Through the partnership, Delve Bio will leverage Broad Clinical Labs' sequencing capability to accelerate the commercialization of its metagenomic assay.